title: A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
abstract: OBJECTIVE
  To compare alendronate 70 mg once weekly (OW) with risedronate 35 mg OW with respect to change in bone mineral density (BMD), biochemical markers and upper gastrointestinal (UGI) tolerability over 24 months.
  
  
  METHODS
  This was a 12-month extension to the Fosamax Actonel Comparison Trial international study (FACTS). Postmenopausal women with osteoporosis randomly assigned to either alendronate 70 mg OW or risedronate 35 mg OW for the 12-month base study continued taking the same double-blind study medication. Efficacy measurements were BMD at the hip trochanter, lumbar spine, total hip, and femoral neck and levels of four bone turnover markers at 24 months. The primary hypothesis was that alendronate would produce a greater mean per cent increase from baseline in hip trochanter BMD at 24 months.
  
  
  RESULTS
  Trochanter BMD increased significantly from baseline to month 24 in both groups, with a significantly larger increase with alendronate: adjusted mean treatment difference of 1.50% (95% confidence interval: 0.74%, 2.26%; p < 0.001). Similar results were seen at all BMD sites. Significant geometric mean per cent decreases (p < 0.001) from baseline were seen for all four bone turnover markers in both groups, with significantly larger decreases (p < 0.001) with alendronate: adjusted mean treatment differences ranged from 8.9% to 25.3%. No significant differences were seen in incidence of UGI or other adverse events.
  
  
  CONCLUSIONS
  Alendronate 70 mg OW yielded significantly greater BMD gains and larger decreases in bone turnover marker levels than risedronate 35 mg OW over 24 months, with no difference in UGI tolerability.
authors.affiliation: Department of Medicine & Therapeutics, University of Aberdeen, Aberdeen, UK. d.m.reid@abdn.ac.uk
authors.forename: D M
authors.initials: DM
authors.lastname: Reid
authors.forename: D
authors.initials: D
authors.lastname: Hosking
authors.forename: D
authors.initials: D
authors.lastname: Kendler
authors.forename: M L
authors.initials: ML
authors.lastname: Brandi
authors.forename: J D
authors.initials: JD
authors.lastname: Wark
authors.forename: J F
authors.initials: JF
authors.lastname: Marques-Neto
authors.forename: G
authors.initials: G
authors.lastname: Weryha
authors.forename: N
authors.initials: N
authors.lastname: Verbruggen
authors.forename: C M
authors.initials: CM
authors.lastname: Hustad
authors.forename: E M
authors.initials: EM
authors.lastname: Mahlis
authors.forename: M E
authors.initials: ME
authors.lastname: Melton
mesh_terms: D015502:Absorptiometry, Photon; D000328:Adult; D000368:Aged; D019386:Alendronate / Q000008:administration & dosage*; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D016723:Bone Remodeling / Q000187:drug effects; D004311:Double-Blind Method; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000503:physiopathology; D000068296:Risedronic Acid; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate